SCHEMBL3532175

SCHEMBL3532175

CC(OCc1cc2nc(Cl)ccc2n1S(=O)(=O)c1ccccc1)C(=O)O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 9/20 0.43
PPARA Q07869 8/20 0.43
PPARD Q03181 5/20 0.43
ALDH3A1 P30838 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
NOD1 Q9Y239 4/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
CXCL8 P10145 1/20 0.36
BCL2 P10415 1/20 0.36
BID P55957 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3531610 1.00 PPARG (0.43) PPARGPPARAPPARDALDH3A1ALDH1A1
SCHEMBL3531013 1.00 PPARG (0.43) PPARGPPARAPPARDALDH3A1ALDH1A1
SCHEMBL3528746 0.86 PPARG (0.43) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL3530747 0.86 PPARG (0.43) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL3532548 0.86 PPARG (0.43) PPARGPPARAPPARDALDH1A1HPGD
SCHEMBL3531264 0.86 PPARG (0.50) PPARGPPARAPPARDALDH3A1ALDH1A1
SCHEMBL3533939 0.84 PPARG (0.53) PPARGPPARAPPARDALDH1A1
SCHEMBL3524542 0.83 PPARG (0.63) PPARGPPARAPPARDPSEN1PSEN2
SCHEMBL3532199 0.83 PPARG (0.53) PPARGPPARAPPARDALDH1A1KDM4E
SCHEMBL21064306 0.82 PPARG (0.43) PPARGPPARAPPARDALDH3A1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7728002-B2 Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors LABORATOIRES FOURNIER S.A. (FR) 2010-06-01 US disclosed
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors LABORATOIRES FOURNIER S.A. (FR) 2009-09-24 US disclosed
US-7557122-B2 Pyrrolopyridine compounds, method of making them and uses thereof LABORATOIRES FOURNIER S.A. (FR) 2009-07-07 US disclosed
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LABORATOIRES FOURNIER S.A. (FR) 2008-08-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090239856-A1 Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors PPARD, PPARA, PPARG PPARG 3/4885PPARA 2/4885PPARD 1/4885
US-20080200495-A1 Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof LIPG, PCSK9, PNLIP PPARG 335/4885PPARA 168/4885PPARD 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.